Escalate Life Sciences
Sanofi, GSK say dual-acting vaccine prevents COVID-19 from omicron in large trial
The Sanofi-GSK shot combines a synthetic version of the coronavirus’ signature “spike” protein with a chemical designed to enhance an immune response.
The vaccine is based on an older technology than the messenger RNA approach underlying Moderna and Pfizer’s products, as well as the viral vectors used by Johnson & Johnson and AstraZeneca. Though the shot still isn’t authorized for use, public health officials believe it and other protein-based shots like it may eventually play a useful role as an alternative option for people who are reluctant to be vaccinated with newer technologies.
Expert advisers to the Food and Drug Administration are scheduled to meet next week to discuss “whether and how” vaccines should be modified as the COVID-19 vaccine pandemic evolves.
Sanofi and GSK only enrolled participants who hadn’t been vaccinated, but they did include study volunteers who had previously been infected. Broadly, the vaccine reduced the incidence of cases in previously infected by 75% compared to placebo, and in omicron-positive, volunteers cases were reduced by 93%.
The companies didn’t release any detailed safety data from the trial other than to state that the vaccine “demonstrated a favorable safety and tolerability profile.”
Earlier this month, Sanofi and GSK announced that a booster based on beta increased immune response to multiple variants of the coronavirus that cause COVID-19, including omicron. The beta-based booster doubled the immune response observed with a booster directed against D614.
In a statement, Thomas Triomphe, Sanofi’s vaccines executive vice president, said the data support the companies’ bid to gain authorization of a beta-based booster. “With the immunogenicity data from our beta-booster vaccine, they support our belief that, in a largely seropositive world, a next-generation beta booster vaccine could provide protection against variants like omicron,” he said.
Sanofi and GSK may not be the first to win FDA authorization of a protein-based COVID-19 vaccine, however. An FDA advisory committee has already recommended clearance of a similar, rival shot from Novavax.
Published June 24, 2022
Jonathan Gardner, Senior Reporter